Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2017-07-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2015年第三次临时股东大会会议决议
Regulatory Filings
2017-07-19 Chinese
关于公司设立以来股本演变情况的说明及其董事、监事、高级管理人员的确认意见
Major Shareholding Notification Classification · 95% confidence The document is a detailed explanation of the company's share capital evolution since its establishment, including multiple capital increases, share transfers, and changes in shareholder structure. It also includes confirmations and opinions from the company's directors, supervisors, and senior management regarding the legality and accuracy of the share capital changes. The document references approvals from regulatory bodies and includes audit and capital verification reports. It is not a financial performance report, earnings release, or a simple announcement. It is a comprehensive disclosure about the company's capital history and related confirmations by management. This fits best with the category of Major Shareholding Notification (MRQ), as it involves detailed disclosures about shareholding changes and capital structure evolution, along with management confirmations. The document length and content indicate it is a full report, not just an announcement or certification. Therefore, the classification is MRQ with high confidence.
2017-07-19 Chinese
内部控制鉴证报告（2016年12月31日）
Regulatory Filings
2017-07-19 Chinese
首次公开发行股票并在创业板上市提示公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of shares by 厦门艾德生物医药科技股份有限公司, including details about the issuance price, subscription process, and underwriting. It is not a full financial report, earnings release, or management discussion. The document is relatively short (1585 characters) and serves as a notification about the stock issuance and listing on the Growth Enterprise Market (创业板). This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2017-07-19 Chinese
中信证券股份有限公司关于公司首次公开发行股票并在创业板上市之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to the initial public offering (IPO) and listing of Xiamen Aide Biomedical Technology Co., Ltd. on the ChiNext board. It contains detailed information about the sponsor (underwriter), the issuer, the internal review process, legal and regulatory compliance, financial audit summaries, risk factors, and the sponsor's conclusion on the IPO. The document is a formal sponsorship letter issued by the underwriting securities firm to support the IPO application. It is not an annual report, earnings release, or other financial report, but rather a regulatory and underwriting document related to the IPO process. This type of document is best classified under Capital/Financing Update (CAP) as it relates to the issuance of new shares and the IPO process.
2017-07-19 Chinese
公司章程（草案）
Regulatory Filings
2017-07-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.